Compare SSSS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSSS | ENTA |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.4M | 382.7M |
| IPO Year | N/A | 2012 |
| Metric | SSSS | ENTA |
|---|---|---|
| Price | $13.70 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $15.67 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 287.4K | 187.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.61% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $7.12 | $6.44 |
| 52 Week High | $14.98 | $17.15 |
| Indicator | SSSS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 41.97 |
| Support Level | $12.79 | $11.92 |
| Resistance Level | $14.38 | $13.97 |
| Average True Range (ATR) | 0.51 | 0.75 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 26.60 | 33.69 |
SuRo Capital Corp is a non-diversified closed-end management investment company. The Company's investment objective is to maximize total return, mainly through capital gains on equity and equity-related investments, and to a lesser extent, income from debt investments. It invests mainly in equity securities of rapidly growing, venture capital-backed emerging companies. Investments are made through direct investments, secondary marketplaces, negotiations with selling stockholders, and investment funds or special purpose vehicles (SPVs). The Company may also invest in private credit, founder equity and warrants, and private investment in public equity (PIPE) transactions of special purpose acquisition companies (SPACs).
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.